What is Adaptive Biotechnologies's earnings per share (EPS)?

Adaptive Biotechnologies (ADPT) reported diluted earnings per share of $-0.39 for fiscal year 2025. This represents a 63.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Adaptive Biotechnologies Financials

ADPT

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Adaptive Biotechnologies (ADPT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ADPT FY2025 2026-05-05

Adaptive's FY2025 revenue jump flowed through unusually well because cost of revenue stayed nearly flat, sharply resetting its loss profile.

Between FY2023 and FY2025, revenue climbed from $170.3M to $277.0M even as cost of revenue edged lower, so the recovery was not just selling more units with the same economics. Gross margin expanded from 55.6% to 74.2%, which points to a materially better mix or delivery efficiency and explains why losses narrowed so quickly once growth returned.

Cash conversion also improved: FY2025 net loss was -$59.5M while operating cash outflow was -$46.0M, so reported losses were no longer being amplified by working-capital drag or other noncash distortions. With capex only $3.0M, this is still a lightly capital-intensive model; most cash use comes from running the business rather than constantly rebuilding its asset base.

Liquidity is healthier than the income statement alone suggests because current assets of $300.2M cover current liabilities of $89.9M, leaving room to absorb normal operating volatility. Still, cash of $70.5M is only about 1.4x one year of current free cash burn, so the company has bought time but has not yet become self-funding.

Financial Health Signals

Financial Health Score 62/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Adaptive Biotechnologies's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Safe

4.46

Adaptive Biotechnologies scores 4.46, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.6B) relative to total liabilities ($287.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Adaptive Biotechnologies passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.77x

For every $1 of reported earnings, Adaptive Biotechnologies generates $0.77 in operating cash flow (-$46.0M OCF vs -$59.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-4.8x

Adaptive Biotechnologies earns $-4.8 in operating income for every $1 of interest expense (-$57.1M vs $11.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$277.0M

YoY+54.8%

5Y CAGR+23.0%

Adaptive Biotechnologies generated $277.0M in revenue in fiscal year 2025. This represents an increase of 54.8% from the prior year.

EBITDA

-$41.1M

YoY+71.7%

Adaptive Biotechnologies's EBITDA was -$41.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 71.7% from the prior year.

Net Income

-$59.5M

YoY+62.7%

Adaptive Biotechnologies reported -$59.5M in net income in fiscal year 2025. This represents an increase of 62.7% from the prior year.

EPS (Diluted)

$-0.39

YoY+63.9%

Adaptive Biotechnologies earned $-0.39 per diluted share (EPS) in fiscal year 2025. This represents an increase of 63.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$48.9M

YoY+50.5%

Adaptive Biotechnologies generated -$48.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 50.5% from the prior year.

Cash & Debt

$70.5M

YoY+47.1%

5Y CAGR-10.6%

Adaptive Biotechnologies held $70.5M in cash against $126.6M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

154M

YoY+4.1%

5Y CAGR+2.2%

Adaptive Biotechnologies had 154M shares outstanding in fiscal year 2025. This represents an increase of 4.1% from the prior year.

Margins & Returns

Gross Margin

74.2%

YoY+14.5pp

5Y CAGR-2.9pp

Adaptive Biotechnologies's gross margin was 74.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 14.5 percentage points from the prior year.

Operating Margin

-20.6%

YoY+70.2pp

5Y CAGR+134.7pp

Adaptive Biotechnologies's operating margin was -20.6% in fiscal year 2025, reflecting core business profitability. This is up 70.2 percentage points from the prior year.

Net Margin

-21.5%

YoY+67.6pp

5Y CAGR+127.2pp

Adaptive Biotechnologies's net profit margin was -21.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 67.6 percentage points from the prior year.

Return on Equity

-27.2%

YoY+51.5pp

5Y CAGR-7.5pp

Adaptive Biotechnologies's ROE was -27.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 51.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$93.8M

YoY-8.9%

5Y CAGR-4.2%

Adaptive Biotechnologies invested $93.8M in research and development in fiscal year 2025. This represents a decrease of 8.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$3.0M

YoY-19.2%

5Y CAGR-30.9%

Adaptive Biotechnologies invested $3.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 19.2% from the prior year.

ADPT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$277.0M+54.8%	$179.0M+5.1%	$170.3M-8.1%	$185.3M+20.1%	$154.3M+56.9%	$98.4M
Cost of Revenue	$71.4M-1.0%	$72.1M-4.6%	$75.6M+30.5%	$57.9M+17.5%	$49.3M+118.8%	$22.5M
Gross Profit	$205.6M+92.4%	$106.9M+12.8%	$94.7M-25.6%	$127.4M+21.3%	$105.0M+38.5%	$75.9M
R&D Expenses	$93.8M-8.9%	$103.0M-15.7%	$122.1M-13.9%	$141.8M-0.4%	$142.3M+22.6%	$116.1M
SG&A Expenses	$72.7M-0.1%	$72.8M-13.3%	$83.9M-5.2%	$88.5M+18.8%	$74.5M+50.4%	$49.5M
Operating Income	-$57.1M+64.9%	-$162.5M+28.4%	-$227.0M-13.4%	-$200.2M+4.2%	-$209.0M-36.7%	-$152.8M
Interest Expense	$11.8M+1.7%	$11.6M-16.1%	$13.8M+225.6%	$4.2M	N/A	N/A
Income Tax	$0	$0	$0	N/A	N/A	N/A
Net Income	-$59.5M+62.7%	-$159.5M+29.2%	-$225.3M-12.5%	-$200.2M+3.4%	-$207.3M-41.8%	-$146.2M
EPS (Diluted)	$-0.39+63.9%	$-1.08+30.8%	$-1.56-11.4%	$-1.40+5.4%	$-1.48-33.3%	$-1.11

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$70.9M-1.1%	$71.7M-23.7%	$94.0M+59.6%	$58.9M+12.3%	$52.4M+10.5%	$47.5M+2.2%	$46.4M+7.5%	$43.2M
Cost of Revenue	$18.7M+2.7%	$18.2M+0.4%	$18.2M+0.9%	$18.0M+6.0%	$17.0M-5.9%	$18.0M+8.3%	$16.7M-13.7%	$19.3M
Gross Profit	$52.2M-2.4%	$53.5M-29.5%	$75.8M+85.5%	$40.9M+15.3%	$35.5M+20.6%	$29.4M-1.2%	$29.8M+24.7%	$23.9M
R&D Expenses	$23.6M+8.5%	$21.8M-8.1%	$23.7M-1.9%	$24.1M-0.3%	$24.2M+4.4%	$23.2M-4.0%	$24.2M-4.7%	$25.4M
SG&A Expenses	$21.0M+7.3%	$19.6M+8.9%	$18.0M+1.0%	$17.8M+2.2%	$17.4M-3.6%	$18.1M+4.6%	$17.3M-3.6%	$17.9M
Operating Income	-$19.2M-50.4%	-$12.8M-224.1%	$10.3M+141.1%	-$25.0M+15.4%	-$29.6M+12.5%	-$33.8M-3.7%	-$32.6M+31.0%	-$47.3M
Interest Expense	$2.9M-2.2%	$3.0M-0.6%	$3.0M+0.8%	$2.9M+1.5%	$2.9M-1.6%	$3.0M+0.4%	$2.9M+9.0%	$2.7M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$20.0M-47.5%	-$13.6M-242.2%	$9.5M+137.3%	-$25.6M+14.2%	-$29.9M+11.4%	-$33.7M-5.1%	-$32.1M+30.6%	-$46.2M
EPS (Diluted)	$-0.13	N/A	$0.06+135.3%	$-0.17+15.0%	$-0.20	N/A	$-0.22+29.0%	$-0.31

ADPT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$512.7M-4.9%	$539.4M-18.4%	$661.1M-22.8%	$856.6M-7.2%	$923.3M-17.3%	$1.1B
Current Assets	$300.2M+5.8%	$283.8M-30.8%	$410.2M-27.0%	$562.1M+39.6%	$402.7M-44.6%	$726.9M
Cash & Equivalents	$70.5M+47.1%	$47.9M-26.3%	$65.1M-27.7%	$90.0M-35.3%	$139.1M+12.7%	$123.4M
Inventory	$9.8M+16.4%	$8.4M-41.6%	$14.4M0.0%	$14.5M-25.0%	$19.3M+37.0%	$14.1M
Accounts Receivable	$50.4M+20.7%	$41.7M+9.9%	$38.0M-5.2%	$40.1M+130.1%	$17.4M+73.3%	$10.0M
Goodwill	$119.0M0.0%	$119.0M0.0%	$119.0M0.0%	$119.0M0.0%	$119.0M0.0%	$119.0M
Total Liabilities	$287.7M-14.6%	$336.9M-4.5%	$352.9M-10.1%	$392.5M+23.0%	$319.2M-14.4%	$373.1M
Current Liabilities	$89.9M-8.3%	$98.1M+11.4%	$88.0M-19.8%	$109.8M-3.5%	$113.8M+8.2%	$105.2M
Long-Term Debt	$126.6M-4.4%	$132.4M+1.3%	$130.7M+4.2%	$125.4M	N/A	N/A
Total Equity	$218.8M+7.9%	$202.7M-34.3%	$308.4M-33.6%	$464.2M-23.2%	$604.0M-18.7%	$743.3M
Retained Earnings	-$1.4B-4.6%	-$1.3B-13.9%	-$1.1B-24.5%	-$919.1M-27.8%	-$718.9M-40.5%	-$511.6M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$505.9M-1.3%	$512.7M+4.5%	$490.6M-1.2%	$496.6M-2.8%	$510.9M-5.3%	$539.4M-3.4%	$558.5M-4.5%	$584.9M
Current Assets	$291.8M-2.8%	$300.2M+6.7%	$281.4M+7.5%	$261.9M+2.1%	$256.5M-9.6%	$283.8M-8.0%	$308.3M-12.3%	$351.6M
Cash & Equivalents	$77.6M+10.1%	$70.5M+28.1%	$55.0M+27.5%	$43.2M-14.8%	$50.6M+5.7%	$47.9M+25.8%	$38.1M-36.3%	$59.8M
Inventory	$11.2M+14.1%	$9.8M-1.1%	$9.9M+18.2%	$8.4M-3.2%	$8.7M+2.9%	$8.4M-29.4%	$12.0M-9.5%	$13.2M
Accounts Receivable	$48.3M-4.1%	$50.4M+12.4%	$44.8M+1.2%	$44.3M+1.6%	$43.6M+4.4%	$41.7M+2.2%	$40.8M+14.6%	$35.6M
Goodwill	$119.0M0.0%	$119.0M0.0%	$119.0M0.0%	$119.0M0.0%	$119.0M0.0%	$119.0M0.0%	$119.0M0.0%	$119.0M
Total Liabilities	$281.7M-2.1%	$287.7M+0.5%	$286.4M-9.7%	$317.1M-1.1%	$320.6M-4.8%	$336.9M+0.6%	$334.9M-2.5%	$343.4M
Current Liabilities	$87.0M-3.2%	$89.9M+7.9%	$83.4M-9.5%	$92.1M+4.9%	$87.8M-10.4%	$98.1M+11.9%	$87.6M-0.6%	$88.1M
Long-Term Debt	$124.7M-1.4%	$126.6M-2.2%	$129.4M-0.8%	$130.5M-0.8%	$131.6M-0.7%	$132.4M-0.2%	$132.7M+0.5%	$132.1M
Total Equity	$216.3M-1.1%	$218.8M+7.0%	$204.4M+13.8%	$179.7M-5.6%	$190.4M-6.1%	$202.7M-9.4%	$223.8M-7.4%	$241.6M
Retained Earnings	-$1.4B-1.5%	-$1.4B-1.0%	-$1.3B+0.7%	-$1.4B-1.9%	-$1.3B-2.3%	-$1.3B-2.7%	-$1.3B-2.6%	-$1.2B

ADPT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$46.0M+51.7%	-$95.2M+39.1%	-$156.3M+15.0%	-$183.9M+4.6%	-$192.7M-28.8%	-$149.7M
Capital Expenditures	$3.0M-19.2%	$3.7M-65.7%	$10.7M-34.6%	$16.3M-73.5%	$61.7M+228.4%	$18.8M
Free Cash Flow	-$48.9M+50.5%	-$98.9M+40.8%	-$167.0M+16.6%	-$200.3M+21.3%	-$254.5M-51.0%	-$168.5M
Investing Cash Flow	$38.0M-51.2%	$77.8M-40.0%	$129.6M+4362.9%	$2.9M-98.4%	$181.2M+254.8%	-$117.0M
Financing Cash Flow	$30.4M+12515.4%	$241K-89.3%	$2.2M-98.3%	$132.3M+387.2%	$27.1M-90.8%	$293.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$9.5M-564.1%	$2.1M+128.8%	-$7.1M+42.7%	-$12.4M+56.4%	-$28.5M-128.0%	-$12.5M+53.8%	-$27.1M-56.4%	-$17.3M
Capital Expenditures	$796K+25.2%	$636K+55.5%	$409K-37.6%	$655K-48.0%	$1.3M+1473.8%	$80K-76.7%	$344K-80.1%	$1.7M
Free Cash Flow	-$10.3M-828.2%	$1.4M+118.8%	-$7.5M+42.4%	-$13.1M+56.0%	-$29.7M-136.6%	-$12.6M+54.1%	-$27.4M-44.0%	-$19.0M
Investing Cash Flow	$9.1M+210.8%	-$8.3M-147.7%	$17.3M+416.5%	$3.3M-86.9%	$25.6M+15.6%	$22.1M+318.4%	$5.3M-10.0%	$5.9M
Financing Cash Flow	$7.5M-65.4%	$21.7M+1186.1%	$1.7M+4.6%	$1.6M-70.5%	$5.5M+4192.1%	$127K+217.5%	$40K+33.3%	$30K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ADPT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	74.2%+14.5pp	59.7%+4.1pp	55.6%-13.1pp	68.8%+0.7pp	68.1%-9.0pp	77.1%
Operating Margin	-20.6%+70.2pp	-90.8%+42.5pp	-133.3%-25.3pp	-108.0%+27.4pp	-135.4%+19.9pp	-155.3%
Net Margin	-21.5%+67.6pp	-89.1%+43.2pp	-132.3%-24.3pp	-108.0%+26.3pp	-134.3%+14.3pp	-148.6%
Return on Equity	-27.2%+51.5pp	-78.7%-5.6pp	-73.0%-29.9pp	-43.1%-8.8pp	-34.3%-14.6pp	-19.7%
Return on Assets	-11.6%+18.0pp	-29.6%+4.5pp	-34.1%-10.7pp	-23.4%-0.9pp	-22.4%-9.3pp	-13.1%
Current Ratio	3.34+0.4	2.89-1.8	4.66-0.5	5.12+1.6	3.54-3.4	6.91
Debt-to-Equity	0.58-0.1	0.65+0.2	0.42+0.2	0.27-0.3	0.53+0.0	0.50
FCF Margin	-17.7%+37.6pp	-55.3%+42.8pp	-98.1%+10.0pp	-108.1%+56.8pp	-164.9%+6.4pp	-171.3%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	73.6%-1.0pp	74.6%-6.1pp	80.7%+11.2pp	69.4%+1.8pp	67.6%+5.6pp	62.0%-2.1pp	64.1%+8.8pp	55.3%
Operating Margin	-27.1%-9.3pp	-17.8%-28.8pp	10.9%+53.5pp	-42.5%+13.9pp	-56.5%+14.8pp	-71.3%-1.0pp	-70.3%+39.3pp	-109.6%
Net Margin	-28.3%-9.3pp	-18.9%-29.1pp	10.2%+53.7pp	-43.5%+13.4pp	-56.9%+14.1pp	-71.0%-1.9pp	-69.1%+38.0pp	-107.0%
Return on Equity	-9.3%-3.1pp	-6.2%-10.9pp	4.7%+18.9pp	-14.2%+1.4pp	-15.7%+0.9pp	-16.6%-2.3pp	-14.3%+4.8pp	-19.1%
Return on Assets	-4.0%-1.3pp	-2.6%-4.6pp	1.9%+7.1pp	-5.2%+0.7pp	-5.8%+0.4pp	-6.3%-0.5pp	-5.7%+2.2pp	-7.9%
Current Ratio	3.35+0.0	3.34-0.0	3.38+0.5	2.84-0.1	2.92+0.0	2.89-0.6	3.52-0.5	3.99
Debt-to-Equity	0.580.0	0.58-0.1	0.63-0.1	0.73+0.0	0.69+0.0	0.65+0.1	0.59+0.0	0.55
FCF Margin	-14.6%-16.6pp	2.0%+10.0pp	-8.0%+14.2pp	-22.2%+34.5pp	-56.7%-30.2pp	-26.5%+32.5pp	-59.0%-15.0pp	-44.1%

Similar Companies

Agios Pharmaceuticals Inc AGIO

$2.2B

Travere Therapeutics Inc TVTX

$5.3B

Tarsus Pharmaceuticals, Inc. TARS

$2.6B

Ideaya Biosciences IDYA

$3.5B

Galapagos Nv GLPG

$1.8B

Frequently Asked Questions

What is Adaptive Biotechnologies's annual revenue?

Adaptive Biotechnologies (ADPT) reported $277.0M in total revenue for fiscal year 2025. This represents a 54.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Adaptive Biotechnologies's revenue growing?

Adaptive Biotechnologies (ADPT) revenue grew by 54.8% year-over-year, from $179.0M to $277.0M in fiscal year 2025.

Is Adaptive Biotechnologies profitable?

No, Adaptive Biotechnologies (ADPT) reported a net income of -$59.5M in fiscal year 2025, with a net profit margin of -21.5%.

What is Adaptive Biotechnologies's EBITDA?

Adaptive Biotechnologies (ADPT) had EBITDA of -$41.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Adaptive Biotechnologies have?

As of fiscal year 2025, Adaptive Biotechnologies (ADPT) had $70.5M in cash and equivalents against $126.6M in long-term debt.

What is Adaptive Biotechnologies's gross margin?

Adaptive Biotechnologies (ADPT) had a gross margin of 74.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Adaptive Biotechnologies's operating margin?

Adaptive Biotechnologies (ADPT) had an operating margin of -20.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Adaptive Biotechnologies's net profit margin?

Adaptive Biotechnologies (ADPT) had a net profit margin of -21.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Adaptive Biotechnologies's return on equity (ROE)?

Adaptive Biotechnologies (ADPT) has a return on equity of -27.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Adaptive Biotechnologies's free cash flow?

Adaptive Biotechnologies (ADPT) generated -$48.9M in free cash flow during fiscal year 2025. This represents a 50.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Adaptive Biotechnologies's operating cash flow?

Adaptive Biotechnologies (ADPT) generated -$46.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Adaptive Biotechnologies's total assets?

Adaptive Biotechnologies (ADPT) had $512.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Adaptive Biotechnologies's capital expenditures?

Adaptive Biotechnologies (ADPT) invested $3.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Adaptive Biotechnologies spend on research and development?

Adaptive Biotechnologies (ADPT) invested $93.8M in research and development during fiscal year 2025.

How many shares does Adaptive Biotechnologies have outstanding?

Adaptive Biotechnologies (ADPT) had 154M shares outstanding as of fiscal year 2025.

What is Adaptive Biotechnologies's current ratio?

Adaptive Biotechnologies (ADPT) had a current ratio of 3.34 as of fiscal year 2025, which is generally considered healthy.

What is Adaptive Biotechnologies's debt-to-equity ratio?

Adaptive Biotechnologies (ADPT) had a debt-to-equity ratio of 0.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Adaptive Biotechnologies's return on assets (ROA)?

Adaptive Biotechnologies (ADPT) had a return on assets of -11.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Adaptive Biotechnologies's cash runway?

Based on fiscal year 2025 data, Adaptive Biotechnologies (ADPT) had $70.5M in cash against an annual operating cash burn of $46.0M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Adaptive Biotechnologies's Altman Z-Score?

Adaptive Biotechnologies (ADPT) has an Altman Z-Score of 4.46, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Adaptive Biotechnologies's Piotroski F-Score?

Adaptive Biotechnologies (ADPT) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Adaptive Biotechnologies's earnings high quality?

Adaptive Biotechnologies (ADPT) has an earnings quality ratio of 0.77x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Adaptive Biotechnologies cover its interest payments?

Adaptive Biotechnologies (ADPT) has an interest coverage ratio of -4.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Adaptive Biotechnologies?

Adaptive Biotechnologies (ADPT) scores 62 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.